Role of Gamma Delta T Cells in Immunotherapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 48
Special Issue Editors
Interests: human gamma/delta T cells; T-cell activation; adoptive immunotherapy; tumor immunology
Special Issues, Collections and Topics in MDPI journals
Interests: disease models in humanized mice; transplantation immunology; viral immunology; tumor immunology; clinical immunology; T lymphocytes; T cells; γδ-T cells; regulatory T cell; NK cells; influenza; immunology; microbiology; infectious diseases; adoptive immunotherapy; cancer
Special Issue Information
Dear Colleagues,
In contrast to conventional CD4 and CD8 T cells expressing the αβ T-cell receptor, T cells carrying the alternative γδ T-cell receptor are not dependent on MHC/HLA-restriction for antigen recognition. Two major subsets of human γδ T cells expressing either Vδ1 or Vδ2 differ in tissue distribution and ligand recognition. Vδ2 T cells dominating the blood recognize pyrophosphate molecules secreted by microbes or overproduced by transformed cells, while Vδ1 T cells are preferentially located in epithelial tissue. γδ T cells are potent cytotoxic effector cells which can kill a broad range of infected or cancerous cells and thus are of great interest for cellular immunotherapies.
This Special Issue explores the potential of γδ T cells in the immunotherapy of cancer and infections. Topics of interest include the differential role of γδ T-cell subsets in immunotherapy and their potential pro- versus anti-tumor activity, potential strategies to enhance the effector functions of γδ T cells (e.g., chimeric antigen receptors, bispecific T-cell engagers, combination with checkpoint inhibitors or epigenetic modifiers), and strategies to overcome the immunosuppressive tumor microenvironment. Moreover, contributions on innovative strategies such as the use of extracellular vesicles rather than intact γδ T cells are also welcome.
Both reviews and original articles are welcome.
Prof. Dr. Dieter Kabelitz
Prof. Dr. Wenwei Tu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gamma delta T cells
- adoptive cell therapy
- chimeric antigen receptors
- bispecific antibodies
- cancer immunotherapy
- tumor microenvironment
- phosphoantigens
- butyrophilin 2A1/3A1
- virus infection
- multidrug-resistant bacteria
- extracellular vesicles
